Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression

• Status: Completed
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Naurex, Inc; Naurex, Inc, an affiliate of Allergan plc

Criteria

Inclusion Criteria:

• diagnosis of major depressive disorder consistent with DSM-IV-TR

• current episode greater than 8 weeks in duration

• Hamilton Depression score >/- 21

• less than 25% reduction in depression during current episode assessed by ATRQ

Exclusion Criteria:

• Axis diagnosis of other psychiatric disorders

• Experiencing hallucinations, delusions, other psychotic symptomatology

• ECT during current episode